Blood and Marrow Transplantation Reviews: Optimal Use of Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin’s Lymphoma
The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving.
Optimal Use of Autologous Transplantation and Stem Cell Mobilization in Patients
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Parameswaran Hari, MD, MRCP, MS Armand Quick-William Stapp Professor of Hematology Interim Chief Hematology and Oncology Medical...BloodLine Presents: Updates on Current Treatment Options for Cytomegalovirus (CMV) in the Transplant Setting
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.
Webcast: Breakthrough Therapies for Acute Graft-Versus-Host-Disease
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers James Ferrara, MD, DSc Program Chair Ward-Coleman Chair in Cancer Medicine Professor and Director Hematologic Malignancies...Blood and Marrow Transplantation Reviews – Optimal Use of Stem Cell Mobilization in Patients with Hematologic Malignancies
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.
Webcast: Utilizing CAR T Cells for Hematologic Malignancies in the Transplant Setting
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Stephan A. Grupp, MD, PhD Program Chair Director of the Cancer Immunotherapy Program Director of Translational Research for the Center...Webcast – Updates on Hematologic Malignancies: New Targeted Conditioning Regimens
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Sergio A. Giralt, MD Program Chair Professor of Medicine Weill Cornell College of Medicine Chief Attending, Adult BMT Service Memorial...Webcast: Breakthrough Therapies for Graft-Versus-Host-Disease
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers James Ferrara, MD, DSc Program Chair Ward-Coleman Chair in Cancer Medicine Professor and Director Hematologic Malignancies...Blood and Marrow Transplantation Reviews: Breakthrough Therapies for Acute Graft-Versus-Host-Disease
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.